Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Urogen Pharma Ltd (NQ: URGN )

13.37 +0.46 (+3.56%)
Streaming Delayed Price Updated: 2:21 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Urogen Pharma Ltd

< Previous 1 2 3 4 5 6 Next >
UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto® in Israel
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Report Second Quarter 2021 Financial Results on Wednesday, August 4, 2021
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021
From UroGen Pharma Ltd.
Via Business Wire
The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 12) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures COVID-19
Stocks That Hit 52-Week Lows On Monday
On Monday morning, 16 companies achieved new lows for the year. Points of Interest: The largest company in terms of market cap to set a new 52-week low was Tencent... 
Via Benzinga
UroGen Pharma to Present at Ladenburg Thalmann Healthcare Conference
From UroGen Pharma Ltd
Via Business Wire
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma Announces June 2021 Conference Schedule
From UroGen Pharma Ltd.
Via Business Wire
Looking Into UroGen Pharma's Return On Capital Employed
UroGen Pharma (NASDAQ:URGN) reported Q1 sales of $7.49 million. Earnings fell to a loss of $26.11 million, resulting in a 4.18% decrease from last quarter. In Q4, UroGen Pharma... 
Via Benzinga
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures Product Safety
77 Biggest Movers From Yesterday
Gainers AMC Entertainment Holdings, Inc. (NYSE: AMC) shares surged 23.7% to close at $12.77. Moxian, Inc. (NASDAQ: MOXC) jumped 23.6% to close at $9.52. Repro Med Systems, Inc... 
Via Benzinga
44 Stocks Moving In Thursday's Mid-Day Session
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) jumped 38.7% to $4.0901 after the company said it has acquired a premier health insurance agency, J.P. Kush and Associates, Inc... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning session, 24 stocks hit new 52-week lows. Facts of Interest: American Well (NYSE:AMWL) was the largest firm by market cap to set a new... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures COVID-19
UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
UroGen Pharma to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
From UroGen Pharma Ltd.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Tuesday morning, 38 companies set new 52-week lows. Key Facts: Viatris (NASDAQ:VTRS) was the largest company by market cap to set a new 52-week low. Enservco (AMEX:... 
Via Benzinga
Earnings Scheduled For May 13, 2021
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million. •... 
Via Benzinga
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.